IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

PURPOSE To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations in acute myeloid leukemia (AML). PATIENTS AND METHODS We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian AML Study Group (AMLSG) treatment trials AML HD98A and APL HD95 for mutations in exon 4 of IDH1 and IDH2. Patients were also studied for NPM1, FLT3, MLL, and CEBPA mutations. The median follow-up for survival was 6.3 years. RESULTS IDH mutations were found in 129 patients (16.0%) -IDH1 in 61 patients (7.6%), and IDH2 in 70 patients (8.7%). Two patients had both IDH1 and IDH2 mutations. All but one IDH1 mutation caused substitutions of residue R132; IDH2 mutations caused changes of R140 (n = 48) or R172 (n = 22). IDH mutations were associated with older age (P < .001; effect conferred by IDH2 only); lower WBC (P = .04); higher platelets (P < .001); cytogenetically normal (CN) -AML (P< .001); and NPM1 mutations, in particular with the genotype of mutated NPM1 without FLT3 internal tandem duplication (ITD; P < .001). In patients with CN-AML with the latter genotype, IDH mutations adversely impacted relapse-free survival (RFS; P = .02) and overall survival (P = .03), whereas outcome was not affected in patients with CN-AML who lacked this genotype. In CN-AML, multivariable analyses revealed a significant interaction between IDH mutation and the genotype of mutated NPM1 without FLT3-ITD (ie, the adverse impact of IDH mutation [RFS]; P = .046 was restricted to this patient subset). CONCLUSION IDH1 and IDH2 mutations are recurring genetic changes in AML. They constitute a poor prognostic factor in CN-AML with mutated NPM1 without FLT3-ITD, which allows refined risk stratification of this AML subset.

[1]  W. Dinjens,et al.  Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. , 2010, The Journal of clinical endocrinology and metabolism.

[2]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[3]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[4]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[5]  N. Yoo,et al.  Absence of IDH2 codon 172 mutation in common human cancers , 2009, International journal of cancer.

[6]  T. Haferlach,et al.  IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients , 2009 .

[7]  Ö. Alkan,et al.  L-2-Hydroxyglutaric Aciduria and Brain Tumors: A Case Report and Review of the Literature , 2009 .

[8]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[9]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[11]  N. Yoo,et al.  Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers , 2009, International journal of cancer.

[12]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[13]  D. Ellison,et al.  Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children , 2009, Cell cycle.

[14]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[15]  P. Kleihues,et al.  Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome , 2009, Acta Neuropathologica.

[16]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[17]  A. Marchetti,et al.  IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.

[18]  E. Schaftingen,et al.  l-2-Hydroxyglutaric aciduria, a disorder of metabolite repair , 2009, Journal of Inherited Metabolic Disease.

[19]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[20]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[21]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[22]  K. Döhner,et al.  Risk-Adapted Therapy in Younger Adults with Acute Myeloid Leukemia: Results of the AMLHD98A Trial of the AMLSG. , 2006 .

[23]  S. Fröhling,et al.  High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia , 2005, Leukemia.

[24]  W. Craigen,et al.  Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. , 2005, American journal of human genetics.

[25]  T. Huh,et al.  Cytosolic NADP+-dependent Isocitrate Dehydrogenase Plays a Key Role in Lipid Metabolism* , 2004, Journal of Biological Chemistry.

[26]  T. Huh,et al.  Role of NADP+‐dependent isocitrate dehydrogenase (NADP+‐ICDH) on cellular defence against oxidative injury by γ‐rays , 2004 .

[27]  Jianping Ding,et al.  Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity* , 2004, Journal of Biological Chemistry.

[28]  C. Bloomfield,et al.  Cytogenetics in acute leukemia. , 2004, Blood reviews.

[29]  G. Finocchiaro,et al.  L-2-hydroxyglutaric aciduria and brain malignant tumors , 2004, Neurology.

[30]  K. Narahara,et al.  Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3 , 2004, Human Genetics.

[31]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Felix W. Frueh,et al.  The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics , 2003, Clinical chemistry and laboratory medicine.

[33]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[34]  D. Grimwade.  The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[35]  Su-Min Lee,et al.  Control of Mitochondrial Redox Balance and Cellular Defense against Oxidative Damage by Mitochondrial NADP+-dependent Isocitrate Dehydrogenase* , 2001, The Journal of Biological Chemistry.

[36]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[37]  B. Geisbrecht,et al.  The Human PICD Gene Encodes a Cytoplasmic and Peroxisomal NADP+-dependent Isocitrate Dehydrogenase* , 1999, The Journal of Biological Chemistry.

[38]  A. Nekrutenko,et al.  Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. , 1998, Molecular biology and evolution.

[39]  T. Huh,et al.  Assignment of the human mitochondrial NADP(+)-specific isocitrate dehydrogenase (IDH2) gene to 15q26.1 by in situ hybridization. , 1996, Genomics.

[40]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[41]  R. Haselbeck,et al.  Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases. , 1993, The Journal of biological chemistry.

[42]  E. Korn.  Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.

[43]  G. Plaut,et al.  The subcellular location of isozymes of NADP-isocitrate dehydrogenase in tissues from pig, ox and rat. , 1983, Biochimica et biophysica acta.

[44]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .